Despite being highly effective and beneficial for many patients, unexpected consequences are emerging in patients who are prescribed（规定的，指示） proton pump inhibitors（质子泵抑制剂） (PPIs) for reflux（逆流，退潮） diseases. Physicians are warned to monitor these effects and prescribe these medications carefully, according to a new commentary published in the November 2009 issue of Otolaryngology – Head and Neck Surgery. According to the authors, gastroesophageal（胃食管的） reflux(GERD) and laryngopharyngeal（咽喉的） reflux (LPR) are diseases that have undergone a remarkable¹ growth in public health relevance² over the last 20 years. While it has been known historically that more than 50 percent of adults in Western countries have occasional symptoms of reflux, there has been a more than four-fold increase in how many patients seek medical care for their symptoms.

PPIs are a class of important and generally safe medicines that prevent the release of stomach acid（酸）, which is one cause of the burning sensation many reflux patients experience. PPIs are among the most widely prescribed classes of medications for GERD and LPR diseases. But according to the authors, there is a growing body of literature demonstrating that acid is not the only causal agent of tissue damage in reflux disease, and that PPIs are not effective at treating all cases of GERD and LPR.

In addition to the evidence that acid isn't the only contributing agent in reflux disease, the authors' search of recent research on PPIs pointed³ out that there are many unexpected consequences and side effects from this class of drugs. They can include: increased rates of hip⁴ fractures（部骨折）, possibly related to altered calcium⁵ absorption（吸收）; possible but yet unproven altered vitamin B12 and iron absorption, related to alteration⁶ of the gastric⁷（胃的） pH; increased odds⁸ of acquiring nosocomial（医院的） Clostridium difficile-associated diarrhea（痢疾，腹泻）; and increased odds of contracting community-acquired pneumonia⁹.

The authors say while it may be premature¹⁰ to make global recommendations about PPI prescribing patterns, they applaud the idea of raising clinical awareness¹¹ of this medication class and its potential unexpected consequences. In addition, appropriate evaluation¹² and monitoring of patients taking PPIs will be important in determining the need and duration of the use of the medications. The authors further advise physicians treating reflux disease patients to weigh the risks of treatment versus¹³ the risks of not treating the disease, and to consider a goal of a more holistic¹⁴（整体的，全盘的） approach that includes diet and lifestyle modification¹⁵. These additional steps could prove beneficial in lowering healthcare costs associated with reflux diseases, and encourage patients to continue practicing behaviors that would improve their overall health.